» Articles » PMID: 33827699

Are Radiomics Features Universally Applicable to Different Organs?

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2021 Apr 8
PMID 33827699
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many studies have successfully identified radiomics features reflecting macroscale tumor features and tumor microenvironment for various organs. There is an increased interest in applying these radiomics features found in a given organ to other organs. Here, we explored whether common radiomics features could be identified over target organs in vastly different environments.

Methods: Four datasets of three organs were analyzed. One radiomics model was constructed from the training set (lungs, n = 401), and was further evaluated in three independent test sets spanning three organs (lungs, n = 59; kidneys, n = 48; and brains, n = 43). Intensity histograms derived from the whole organ were compared to establish organ-level differences. We constructed a radiomics score based on selected features using training lung data over the tumor region. A total of 143 features were computed for each tumor. We adopted a feature selection approach that favored stable features, which can also capture survival. The radiomics score was applied to three independent test data from lung, kidney, and brain tumors, and whether the score could be used to separate high- and low-risk groups, was evaluated.

Results: Each organ showed a distinct pattern in the histogram and the derived parameters (mean and median) at the organ-level. The radiomics score trained from the lung data of the tumor region included seven features, and the score was only effective in stratifying survival for other lung data, not in other organs such as the kidney and brain. Eliminating the lung-specific feature (2.5 percentile) from the radiomics score led to similar results. There were no common features between training and test sets, but a common category of features (texture category) was identified.

Conclusion: Although the possibility of a generally applicable model cannot be excluded, we suggest that radiomics score models for survival were mostly specific for a given organ; applying them to other organs would require careful consideration of organ-specific properties.

Citing Articles

Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.

Beaumont H, Iannessi A, Thinnes A, Jacques S, Quintas-Cardama A Cancers (Basel). 2025; 17(3).

PMID: 39941830 PMC: 11816047. DOI: 10.3390/cancers17030463.


Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.

Tompkins A, Gray Z, Dadey R, Zenkin S, Batavani N, Newman S J Immunother Cancer. 2025; 13(2).

PMID: 39939139 PMC: 11822426. DOI: 10.1136/jitc-2024-009568.


CT and MRI radiomic features of lung cancer (NSCLC): comparison and software consistency.

Bortolotto C, Pinto A, Brero F, Messana G, Cabini R, Postuma I Eur Radiol Exp. 2024; 8(1):71.

PMID: 38880866 PMC: 11180643. DOI: 10.1186/s41747-024-00468-8.


Biodistribution Assessment of a Novel Ga-Labeled Radiopharmaceutical in a Cancer Overexpressing CCK2R Mouse Model: Conventional and Radiomics Methods for Analysis.

Pavone A, Benfante V, Giaccone P, Stefano A, Torrisi F, Russo V Life (Basel). 2024; 14(3).

PMID: 38541733 PMC: 10972008. DOI: 10.3390/life14030409.


Development and Validation of CT-Based Radiomics Signature for Overall Survival Prediction in Multi-organ Cancer.

Le V, Kha Q, Minh T, Nguyen V, Le V, Le N J Digit Imaging. 2023; 36(3):911-922.

PMID: 36717518 PMC: 10287593. DOI: 10.1007/s10278-023-00778-0.


References
1.
Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

2.
Wang C, Subashi E, Yin F, Chang Z . Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI. Med Phys. 2016; 43(3):1335-47. PMC: 4760981. DOI: 10.1118/1.4941739. View

3.
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013; 26(6):1045-57. PMC: 3824915. DOI: 10.1007/s10278-013-9622-7. View

4.
Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

5.
Song S, Park H, Lee G, Lee H, Sohn I, Kim H . Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma. J Thorac Oncol. 2016; 12(4):624-632. DOI: 10.1016/j.jtho.2016.11.2230. View